Catheter Outcomes in the Short-term Inpatient Setting: A Controlled Quality Improvement Study Comparing Citrate and Heparin Lock

Seminars in Dialysis

Volumn 25, Issue 3, 2012, Pages 351-356

  Parikh, Samir ^a   Nijmeh, Ruba ^a   Van Cleef, Sheri ^a   Timmerman, Sue ^a   Bhatt, Udayan Y ^a   Agarwal, Anil K ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CITRIC ACID; HEPARIN;

ARTICLE; CATHETER INFECTION; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; FEMALE; FOLLOW UP; HUMAN; INDWELLING CATHETER; INSTRUMENTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; STANDARD; TIME; TOTAL QUALITY MANAGEMENT;

ANTICOAGULANTS; CATHETER-RELATED INFECTIONS; CATHETERS, INDWELLING; CITRIC ACID; FEMALE; FOLLOW-UP STUDIES; HEPARIN; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY IMPROVEMENT; RENAL DIALYSIS; TIME FACTORS;

EID: 84861233826     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2011.00966.x     Document Type: Article

References (20)

1. NKF-K/DOQI Clinical Practice Guidelines for Vascular Access. Update 2006. Available at, accessed May 12, 2011
2. Rayner HC, Besarab A, Brown WW, Disney A, Saito A, Pisoni RL: Vascular access results from the Dialysis Outcomes and Practice Patterns Study (DOPPS): performance against Kidney Disease Outcomes Quality Initiative (K/DOQI) Clinical Practice Guidelines. Am J Kidney Dis 44:S22-S26, 2004
3. Moran JE, Ash S, Clinical Practice Committee: Locking solutions for hemodialysis catheters; heparin and citrate - a Position Paper by ASDIN. Semin Dial 21:490-492, 2008
4. Hemmelgarn BR, Moist LM, Lok CE, Tonelli M, Manns BJ, Holden RM, LeBlanc M, Faris P, Barre P, Zhang J, Scott-Douglas N: Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator. N Engl J Med 364:303-312, 2011
5. Sungur M, Eryuksell E, Yavas S, Bihorac A, Layon J, Caruso L: Exit of catheter lock solutions from double lumen acute hemodialysis catheters: an in vitro study. Nephrol Dial Transplant 22:3533-3537, 2007
6. Karaaslan H, Peyronnet P, Benevent D, Lagarde C, Rince M, Leroux-Robert C: Risk of heparin lock-related bleeding when using indwelling venous catheters for hemodialysis. Nephrol Dial Transplant 16:2072-2074, 2001
7. Shanks R, Sargent J, Martinez R, Graber M, O'Toole G: Catheter lock solutions influence staphylococcal biofilm formation on abiotic surfaces. Nephrol Dial Transplant 21:2247-2255, 2006
8. Shanks R, Donegan N, Graber M, Buckingham S, Zegans M, Cheung A, O'Toole G: Heparin stimulates staphylococcal biofilm formation. Infect Immun 73:4596-4606, 2005
9. Burry L, Tung D, Hallet D, Bailie T, Carvalbana V, Lee D, Ramganesh S, Richardson R, Mehta S, Lapinsky S: Regional citrate anticoagulation for Prismaflex continuous renal replacement therapy. Ann Pharmacol 43:1419-1425, 2009
10. Oudemans-van Straaten H: Citrate anticoagulation for continuous renal replacement therapy in the critically ill. Blood Purif 29:191-196, 2010
11. Weijmer MC, Van den Dorpel MA, Van de Ven PJG, ter Wee PM, van Geelen JACA, Groeneveld JO, van Jaarsveld BC, Koopmans MG, lePoole CY, Schrander-Van der Meer AM, Siegert CEH, Stas KJF for the CITRATE study group. Randomized, clinical trial comparison of trisodium citrate 30% and heparin as catheter-locking solution in hemodialysis patients. J Am Soc Nephrol 16:2769-2777, 2005
12. Bayes B, Bonal J, Romero R: Sodium citrate for filling hemodialysis catheters. Nephrol Dial Transplant 14:2532-2533, 1999
13. Stas K, Vanwalleghem J, De Moor B, Keuleers H: Trisodium citrate 30% vs. heparin 5% as catheter lock in the interdialytic period in twin or double-lumen hemodialysis catheter for intermittent hemodialysis. Nephrol Dial Transplant 16:1521-1522, 2001
14. Lok CE, Appleton D, Bhola C, Khoo B, Richardson RM: Trisodium citrate 4%- an alternative to heparin capping of hemodialysis catheters. Nephrol Dial Transplant 22:447-483, 2007
15. MacRae J, Dojcinovic I, Djurdjev O, Jung B, Shalansky S, Levin A, Kiali M: Citrate 4% versus Heparin and the Reduction of Thrombosis Study (CHARTS). Clin J Am Soc Nephrol 3:369-374, 2008
16. Power A, Duncan N, Singh S, Brown W, Dalby E, Edwards C, Lynch K, Prout V, Caims T, Griffith M, McLean A, Palmer A, Taube D: Central venous catheter locks: heparin versus citrate. Am J Kidney Dis 53:1034-1041, 2009
17. Bosma JW, Siegert CE, Peerbooms PG, Weijmer MC: Reduction of biofilm formation with TSC in hemodialysis catheters: a randomized controlled trial. Nephrol Dial Transplant 25:1213-1217, 2010
18. Weijmer MC, Debets-Ossenkopo YJ, Van De Vandervoort FJ, ter Wee PM: Superior antimicrobial activity of trisodium citrate over heparin for catheter locking. Nephrol Dial Transplant 17:2189-2195, 2002
19. Polaschegg HD, Sodemann K: Risks related to catheter locking solutions containing concentrated citrate. Nephrol Dial Transplant 18:2688-2690, 2003
20. FDA: Food and Drug Administration. FDA Issues Warning on Tricitrasol Dialysis Catheter Anticoagulant. FDA Talk Paper, 2000:T00-16 U.S. Department of Health and Human Services. Public Health Service 5600 Fishers Lane Rockville, MD 20857